Vitamin D is a fat-soluble vitamin the body uses to absorb calcium and maintain bone, and its bone role is firmly established: the National Academies' dietary reference values, set in 2011, recommend 600 IU daily for adults up to age 70 and 800 IU above it. What remains far less settled is nearly everything else the vitamin is credited with — the VITAL trial, a randomized study of nearly 26,000 adults published in The New England Journal of Medicine in 2019, found that 2,000 IU daily did not significantly lower the risk of invasive cancer or major cardiovascular events. This article publishes information, not medical advice.
What is vitamin D, and where does it come from?
Vitamin D is a fat-soluble vitamin that functions as a hormone precursor: the skin synthesizes it upon ultraviolet exposure, and it is also obtained from a short list of foods — fatty fish, egg yolks, fortified milk and cereals in the US food supply, per the National Institutes of Health's Office of Dietary Supplements fact sheet, most recently revised in 2024. The activated form helps the intestine absorb calcium and phosphorus, which is the mechanism behind its bone role.
Synthesis varies with latitude, season, skin tone, sunscreen use, and age, which is why the NIH lists breastfed infants, older adults, and people with limited sun exposure among groups at risk of low intake.
What is the evidence for bone health?
Strong and long-standing. Deficiency causes rickets in children and osteomalacia — soft bones — in adults, a connection documented for over a century. The 2011 National Academies review established the current intake values on the basis of bone outcomes, and the NIH's fact sheet notes that combined calcium and vitamin D supplementation has been shown in some trials of older adults, particularly those in institutional care, to reduce fracture risk. The evidence in the general healthy population is weaker, and the National Academies' report was explicit that claims beyond bone health did not then meet the evidentiary bar.
What did the VITAL trial actually find?
VITAL, run at Brigham and Women's Hospital and published in The New England Journal of Medicine in January 2019, randomized 25,871 adults to 2,000 IU of vitamin D3 daily or placebo for a median of 5.3 years. The primary findings: no significant reduction in invasive cancer or major cardiovascular events. A secondary analysis found a possible reduction in cancer deaths that emerged over time — a finding the investigators themselves labeled exploratory, exactly the kind of result that preliminary framing exists for. Earlier observational work had associated low blood vitamin D with many diseases; VITAL tested the causal direction and, for cancer and heart disease, did not confirm it. Observational associations, as the trial demonstrated, can reflect confounding — people with low vitamin D often differ in other ways.
What about immunity and other claims?
Mixed and modest. A 2017 pooled analysis of randomized trials in The BMJ found that vitamin D supplementation was associated with a modest reduction in acute respiratory infection, with the strongest effect in people with low baseline levels — an association across trials, not a settled preventive. Large trials of vitamin D in depression, type 2 diabetes, and multiple sclerosis have been null or inconclusive, per the NIH's evidence summaries. The honest summary: bone is established, infection is suggestive, most else is open.
How much is too much?
The National Academies set the tolerable upper intake level at 4,000 IU daily for adults; above that, the risk rises of hypercalcemia — elevated blood calcium — which can cause nausea, weakness, and, at sustained high levels, kidney damage, per the NIH fact sheet. Very high-dose supplementation has produced harm in trials: a study of high monthly doses in older adults found increased falls. Blood testing is generally reserved for people with risk factors, since the USPSTF has found the evidence insufficient to screen asymptomatic adults.
What remains uncertain?
Whether benefits differ by baseline blood level — most trials, including VITAL, did not require deficiency at entry — and whether long-term supplementation has effects a five-year trial cannot detect. The research continues, and current guidance is written in full awareness of those gaps.
When should someone see a clinician?
Persistent bone pain, muscle weakness, or unexplained fractures warrant evaluation, as does a diagnosis of a malabsorption condition such as celiac or Crohn's disease. Anyone considering doses above the recommended intakes, or taking supplements alongside prescribed medications, should discuss it with a clinician first — the upper limit exists because more is demonstrably not always better.
For more context, read What to Know About Dietary Fiber.
For more context, read What the Research Actually Says About Creatine.
For more context, read How HPV Vaccination Actually Lowers Cervical Cancer Risk.